Latest Cetuximab Stories
Correlation of protein phenotype brings researchers one step closer to personalized cancer treatment MET protein levels correlate strongly with epithelial-mesenchymal transition (EMT) phenotype, a treatment-resistant type of colorectal cancer and may be used as a surrogate biomarker, according to new research from The University of Texas MD Anderson Cancer Center. The study results, which compared MET protein expression with protein/gene expression of EMT markers and evaluated impact on...
A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research. Preliminary data published in this study showed human tumors with MET amplification, grown in mice, responded to MET...
Data Demonstrate Evidence of Indoximod's Safety and Anti-Tumor Activity When Used in Combination with Other Anti-Cancer Agents in Metastatic Solid Tumors AMES, Iowa, June 3, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway. Indoximod was tested...
In a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), high-dose (HD), compared with standard-dose (SD), radiotherapy (RT) with concurrent chemotherapy (CT) did not improve overall survival of patients with stage III non-small-cell lung cancer (NSCLC). Of all the patients in the US with lung cancer, the country's leading cause of cancer death, 75 to 80 percent of them have NSCLC, with 30 to 40 percent of those being considered locally advanced...
Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix(®) (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive...
THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago. "The data that we are presenting at ASCO demonstrate great progress with our effort to develop treatments that will help patients with advanced cancers," said Sean E. Harper, M.D., executive vice president...
Study Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting THOUSAND OAKS, Calif., May 7, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 head-to-head ASPECCT ('763) trial evaluating Vectibix(®) (panitumumab) versus Erbitux(®) (cetuximab) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint of non-inferiority for overall survival. The...
Trial Results to be Submitted For U.S. Marketing Approval Under FDA Fast Track Designation For Promising New Therapies AUSTIN, Texas, Apr. 24, 2013 /PRNewswire/ -- XBiotech announced today enrollment of the first patient into its Phase III trial of Xilonix. The Pivotal study is designed to improve health and survival of late stage colorectal cancer patients with associated cachexia. The patient was enrolled by Dr. Eric Roeland at UC San Diego's Moores Cancer Center. The study is...
WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., March 25, 2013 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Stivarga(®) (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC). In September 2012, Stivarga was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with mCRC who have been...
HILDEN, Germany and GERMANTOWN, Maryland, January 30, 2013 /PRNewswire/ -- - Momentum builds for therascreen(R)KRAS RGQ PCR Kit and Rotor-Gene Q MDx instrument - Clarient offers network of 2,000-plus pathologists testing with therascreen KRAS RGQ PCR Kit, the only FDA-approved KRAS companion diagnostic for Erbitux(R)in metastatic colorectal cancer - KRAS launch prepares way for QIAGEN's growing pipeline of...
